Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Roche Holding AG Basel American Depositary Shares (OP: RHHBY )

38.01 +0.16 (+0.42%)
Streaming Delayed Price Updated: 2:47 PM EST, Jan 23, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 868,227
Open 37.78
Bid (Size) N/A (0)
Ask (Size) N/A (0)
Prev. Close 37.85
Today's Range 37.60 - 38.04
52wk Range 29.20 - 42.43
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Legal Marijuana Linked To Drop In Anxiety Medications: What It Means For Pharma Giants
Medical marijuana reduces benzodiazepine prescriptions, saving patients from potential risks. This threatens big pharma's profits. 
Via Benzinga
Topics Cannabis
Exposures Cannabis
Outlook Therapeutics Vision Loss Drug At Par With Novartis Drug
Outlook Therapeutics plans to resubmit ONS-5010 for FDA approval in 2025 following NORSE EIGHT trial results in wet AMD patients. 
Via Benzinga
Exposures Product Safety

Performance

YTD
+8.79%
+8.79%
1 Month
+8.94%
+8.94%
3 Month
-5.45%
-5.45%
6 Month
-1.38%
-1.38%
1 Year
+8.29%
+8.29%

More News

Read More
Regeneron Pharmaceuticals Slumps As Sales Of High-Dose Eylea Disappoint
Via Investor's Business Daily
Biotech Stocks Prepare For Action In 2025. Weight-Loss Drugs, AI And Trump 2.0 Are The Catalysts.
Via Investor's Business Daily
Topics Artificial Intelligence Government
Exposures Artificial Intelligence Political
Sangamo Therapeutics Stock Plunges As Pfizer Terminates Hemophilia Gene Therapy Pact
Via Benzinga
Roche CEO Reassures No Job Cuts Despite Challenges: Report
Via Benzinga
Topics Workforce
Exposures Layoff
Prothena Catapults, Flashing A Bullish Sign, On Promise In Parkinson's Disease
Via Investor's Business Daily
Roche-Prothena Partnered Mid-Stage Parkinson's Trial Misses Primary Endpoint, But Cling On Signs Of Clinical Benefits
Via Benzinga
Genentech’s Phase IIb Study of Prasinezumab Missed Primary Endpoint, but Suggests Possible Benefit in Early-Stage Parkinson’s Disease
From Genentech
Via Business Wire
Teva Pharmaceutical Releases Impressive Phase 2 Candidate Data For Gastro-Related Diseases
Via Benzinga
Merck Joins The Weight-Loss Race, Inking $2.01 Billion Deal To Take On Eli Lilly, Pfizer, Roche
Via Investor's Business Daily
Battle Over Weight-Loss Drugs: Can Eli Lilly, Novo Nordisk Defend Their Turf?
Via Investor's Business Daily
United Kingdom's National Health Service Drug Spending Priorities Questioned in New Analysis
Via Benzinga
New and Updated Data for Genentech’s Fixed-Duration Columvi and Lunsumio at ASH 2024 Reinforce Their Potential to Improve Outcomes for People With Lymphoma
From Genentech
Via Business Wire
Five-Year Results Confirm Genentech’s Polivy Combination Therapy as New Standard of Care for Previously Untreated Aggressive Lymphoma
From Genentech
Via Business Wire
The Intersection of AI, Medicine, and Stocks: A New Era of Opportunities
Via FinancialNewsMedia
Topics Artificial Intelligence
Exposures Artificial Intelligence
FDA Accepts Supplemental Biologics License Application for Genentech’s Columvi Combination for People With Relapsed or Refractory Diffuse Large B-Cell Lymphoma
From Genentech
Via Business Wire
Artificial Intelligence (AI) Redefining Medical Diagnostics Industry That’s Expected to be a $7.2 Billion Market by 2029
Via FinancialNewsMedia
Topics Artificial Intelligence
Exposures Artificial Intelligence
Avant Technologies’ Partner, Ainnova, Signs Pilot Program with Roche to Combat Diabetic Retinopathy
Via FinancialNewsMedia
Topics Artificial Intelligence
Exposures Artificial Intelligence
NVIDIA Invested in These 2 AI Stocks, Should You?
Via MarketBeat
Topics Artificial Intelligence
Exposures Artificial Intelligence Product Safety
Why Is Eye Disease-Focused Outlook Therapeutics Stock Trading Lower On Wednesday?
Via Benzinga
Roche's Proposed Acquisition Of Poseida Therapeutics Poised To Establish New Core Capability In Cell Therapy For Cancer And Autoimmune Diseases: Details
Via Benzinga
Genentech Reports Update on Phase III SKYSCRAPER-01 Study Results
From Genentech
Via Business Wire
Weight-Loss Drugs Don't Seem To Impress RFK Jr. Should Eli Lilly, Novo Nordisk Investors Worry?
Via Investor's Business Daily
Cidara Therapeutics' Unique Cloudbreak Platform And Its Promise In Influenza And Oncology
Via Talk Markets
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.